Aptose presents safety, response, MRD clinical data from TUSCANY trial

Written by Emily J. Thompson, Senior Investment Analyst

APTO%

Updated: Jun 12 2025

0mins

TUSCANY Trial Results: Aptose Biosciences presented data from the Phase 1/2 TUSCANY trial, showing that the combination of tuspetinib with venetoclax and azacitidine is a promising treatment for newly diagnosed AML patients who cannot undergo induction chemotherapy, with no dose-limiting toxicities reported so far.
Efficacy and Safety Findings: The trial demonstrated encouraging results, including complete remission in several patients across different genetic backgrounds, and confirmed that tuspetinib can be safely administered alongside standard care without significant adverse effects.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Aptose presents safety, response, MRD clinical data from TUSCANY trial

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Micron Technology (MU) to Acquire Taiwanese Chip Fab for $1.8B

UPS Stock Rises Nearly 30% Ahead of Earnings Report on January 27

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch